Preliminary clinical data show that higher NEAT1 and MALAT1 expressions correlate with reduced A3B and increased A3A activities in cancers like breast and lung, suggesting their role in enzymatic balance between A3B and A3A, affecting mutation dynamics and cancer progression. Here, MALAT1 is linked to cancer.